Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q2 2025 value amounting to -$2.0 million.

  • Corvus Pharmaceuticals' Gains from Investment Securities fell 1079.3% to -$2.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$24.8 million, marking a year-over-year decrease of 329922.58%. This contributed to the annual value of $33.4 million for FY2024, which is 322518.73% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Gains from Investment Securities of -$2.0 million as of Q2 2025, which was down 1079.3% from -$25.1 million recorded in Q1 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Gains from Investment Securities peaked at $2.3 million during Q4 2024, and registered a low of -$25.1 million during Q1 2025.
  • For the 4-year period, Corvus Pharmaceuticals' Gains from Investment Securities averaged around -$2.1 million, with its median value being $184360.0 (2022).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 32830.74% in 2024, then plummeted by 874823.94% in 2025.
  • Quarter analysis of 4 years shows Corvus Pharmaceuticals' Gains from Investment Securities stood at -$985000.0 in 2022, then fell by 4.37% to -$1.0 million in 2023, then soared by 328.31% to $2.3 million in 2024, then tumbled by 185.73% to -$2.0 million in 2025.
  • Its Gains from Investment Securities stands at -$2.0 million for Q2 2025, versus -$25.1 million for Q1 2025 and $2.3 million for Q4 2024.